Leerink Partners on Abbott Labs (ABT): U.S. MedTech softness could be viewed unfavorably
Tweet Send to a Friend
Leerink Partners analyst Mike Kratky reiterated a Market Perform rating and $119.00 price target on Abbott Labs (NYSE: ABT)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
